多中心评估:磁共振与超声图像融合引导下经会阴前列腺穿刺活检对既往阴性活检患者行靶向与系统穿刺的比较
这项两中心前瞻性结局研究纳入487例既往经直肠活检良性、2012至2015年接受经会阴MRI/US融合引导靶向与系统饱和穿刺的患者,评估Gleason评分7-10前列腺癌检出率。PI-RADS 3-5病灶见于343例(70%),检出Gleason评分7-10癌149例(31%);结论认为高概率mpMRI病灶需联合靶向与系统穿刺,而PI-RADS 3等不确定病灶单用系统穿刺可能足够。
要点
- PI-RADS 3-5病灶见于343例(70%),Gleason评分7-10前列腺癌检出149例(31%)。
- PI-RADS 1-2对Gleason评分7-10的阴性预测值为0.92(±0.04)。
- PI-RADS 4-5患者中,单用系统穿刺会漏诊12/113(11%)显著前列腺癌,单用靶向穿刺会漏诊10/113(9%)。
核心结论
- 在高概率mpMRI病灶患者中,Gleason评分7-10癌的最高检出率仍需联合靶向与系统MRI/US图像融合穿刺;而PI-RADS 3等不确定病灶单用系统穿刺可能足够。
- 对于PSA密度低且由经验丰富放射科医师判读mpMRI阴性的患者,可能完全无需重复前列腺穿刺。
研究设计与样本
- 两中心前瞻性结局研究,纳入487例既往经直肠活检良性、2012至2015年接受经会阴MRI/US融合引导靶向与系统饱和穿刺的患者。
- 多参数MRI(mpMRI)按前列腺影像报告和数据系统(PI-RADS)第1版报告。
- 主要结局为活检检出Gleason评分7-10前列腺癌。
- 计算阳性预测值(PPV)与阴性预测值(NPV)及95%置信区间(95%CI),靶向与系统穿刺检出率比较采用McNemar检验。
主要发现
- PSA中位数(四分位距)为9.0(6.7-13.4)ng/mL。
- PI-RADS 3-5 mpMRI病灶见于343例(70%),Gleason评分7-10前列腺癌检出149例(31%)。
- 检出Gleason评分7-10前列腺癌的PPV(95%CI):PI-RADS 3为0.20(±0.07),PI-RADS 4为0.32(±0.09),PI-RADS 5为0.70(±0.08)。
- PI-RADS 1-2的NPV(95%CI):Gleason评分7-10为0.92(±0.04),Gleason评分≥4+3癌为0.99(±0.02)。
- 单用系统穿刺发现125/138(91%)Gleason评分7-10癌;PI-RADS 4-5患者中单用系统穿刺会漏诊12/113(11%)显著前列腺癌,单用靶向穿刺会漏诊10/113(9%);PI-RADS 3病灶中单用靶向穿刺会漏诊14/25(56%)Gleason评分7-10癌,单用系统穿刺会漏诊1/25(4%)。
临床怎么用
- 作者结论认为,高概率mpMRI病灶患者应采用靶向与系统穿刺联合以提高Gleason评分7-10癌检出。
- 作者结论认为,PI-RADS 3等不确定病灶单用系统穿刺可能足够。
- 作者结论认为,PSA密度低且经验丰富放射科医师判读mpMRI阴性的患者可能无需重复穿刺。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate the detection rates of targeted and systematic biopsies in magnetic resonance imaging (MRI) and ultrasound (US) image-fusion transperineal prostate biopsy for patients with previous benign transrectal biopsies in two high-volume centres. PATIENTS AND METHODS: A two centre prospective outcome study of 487 patients with previous benign biopsies that underwent transperineal MRI/US fusion-guided targeted and systematic saturation biopsy from 2012 to 2015. Multiparametric MRI (mpMRI) was reported according to Prostate Imaging Reporting and Data System (PI-RADS) Version 1. Detection of Gleason score 7-10 prostate cancer on biopsy was the primary outcome. Positive (PPV) and negative (NPV) predictive values including 95% confidence intervals (95% CIs) were calculated. Detection rates of targeted and systematic biopsies were compared using McNemar's test. RESULTS: The median (interquartile range) PSA level was 9.0 (6.7-13.4) ng/mL. PI-RADS 3-5 mpMRI lesions were reported in 343 (70%) patients and Gleason score 7-10 prostate cancer was detected in 149 (31%). The PPV (95% CI) for detecting Gleason score 7-10 prostate cancer was 0.20 (±0.07) for PI-RADS 3, 0.32 (±0.09) for PI-RADS 4, and 0.70 (±0.08) for PI-RADS 5. The NPV (95% CI) of PI-RADS 1-2 was 0.92 (±0.04) for Gleason score 7-10 and 0.99 (±0.02) for Gleason score ≥4 + 3 cancer. Systematic biopsies alone found 125/138 (91%) Gleason score 7-10 cancers. In patients with suspicious lesions (PI-RADS 4-5) on mpMRI, systematic biopsies would not have detected 12/113 significant prostate cancers (11%), while targeted biopsies alone would have failed to diagnose 10/113 (9%). In equivocal lesions (PI-RADS 3), targeted biopsy alone would not have diagnosed 14/25 (56%) of Gleason score 7-10 cancers, whereas systematic biopsies alone would have missed 1/25 (4%). Combination with PSA density improved the area under the curve of PI-RADS from 0.822 to 0.846. CONCLUSION: In patients with high probability mpMRI lesions, the highest detection rates of Gleason score 7-10 cancer still required combined targeted and systematic MRI/US image-fusion; however, systematic biopsy alone may be sufficient in patients with equivocal lesions. Repeated prostate biopsies may not be needed at all for patients with a low PSA density and a negative mpMRI read by experienced radiologists.
引用
- Hansen NL, Kesch C, Barrett T, et al. Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy. BJU Int. 2016. PMID: 27862869. doi:10.1111/bju.13711
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。